<DOC>
	<DOCNO>NCT01205074</DOCNO>
	<brief_summary>Several factor test see influence methacetin breath test result . Each one factor raise possible source distortion MBT result . I . Variability test subject MBT . Repeatability test healthy individual patient chronic liver disease . II . COPD - Chronic obstructive pulmonary disease lead cause death worldwide , potentially effect MBT since breath test base CO2 production subject may abnormal CO2 production . III . Smoking- 13C Methacetin metabolize healthy hepatocytes reflect hepatic microsomal function CYP1A2 , smoking may cause induction CYP1A2 . Furthermore , internal preliminary data show sign influence smoke MBT range . IV . Age- Empirical data several hundred subject chronic liver disease show age significant factor determine probability disease severity preliminary data normal subject show change MBT age.. Therefore , effect age elucidate orderly fashion . V. CYP450 1A2 Inhibitors- Several drug food item inhibit CYP450 1A2 may affect MBT . VI . Alcohol - Alcohol ingestion lead induction hepatic CYP later stage inhibition due liver damage . Acute alcohol ingestion may therefore effect MBT result . VII . Beta-blockers - beta blocker affect portal hypertension may affect hepatic blood flow thereby outcome methacetin breath test .</brief_summary>
	<brief_title>¹³C-Methacetin Breath Test ( MBT ) Methodology Study</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Inclusion Criteria General Adult subject 18 year age old Women childbearing potential must negative serum urinary hCG pregnancy test within 7 day prior enrollment . During study woman must use 2 method contraception . Subject give write informed consent , prior study related procedure part subject 's normal medical care , understand consent may withdraw time without prejudice future medical care . Exclusion Criteria General Severe heart , pulmonary renal disease . Patient previous surgical bypass surgery morbid obesity Patient extensive small bowel resection Any major surgery past 3 month . Patient recipient organ transplant Pregnant breastfeeding woman . Patient allergic acetaminophen Patients take hepatotoxic drug Patient , base opinion investigator , enrol study . Patients unable unwilling sign inform consent Patients participate clinical trial evaluate experimental treatment procedure participate clinical trial past 3 month . Exclusion Criteria ( Day MBTgeneral ) Patient fast 8 hour . Patient smoke day test . Patient take drug interfere methacetin metabolism : fluvoxamine , amiodarone , ciprofloxacin , cimetidine , rifampin , carbamazepine within last 24 hour . Patient take Tylenol acetaminophen relate medication within past 24 hour . Patients receive new medication last 48 hour . Patients still suffer previous clinical intervention ( e.g . biopsy ) Have consume alcohol 24 hour prior MBT consume regular basis 40gr male 20gr female per day . Inclusion Criteria ( Repeatability ) : Healthy Subjects : No know liver disease Non smoker BMI =2025 kg/m2 Normal liver enzyme ( ALT &lt; 40 U/L men , &lt; 30 U/L woman ) Not take medication No know ongoing chronic medical condition ( apart allergy orthopaedic condition require chronic therapy ) . Normal abdominal ultrasound ( US ) Cirrhotics : Diagnosis cirrhosis liver biopsy Or strong suspicion cirrhosis accept criterion clinical diagnosis cirrhosis ( e.g . peripheral edema varix , palpable hard leave lobe liver , small right lobe span palpable splenomegaly ) , and/or radiological evidence cirrhosis ( abdominal sonography , computer assist axial tomography , magnetic resonance imaging , show nodular liver and/or portosystemic collateral portal vein patency and/or ascites and/or splenomegaly , and/or colloid shift colloidisotope liverspleen scan ) , and/or laboratory variable ( platelet &lt; 100,000/mm3 , albumin &lt; 3.5g/dL , INR &gt; 1.3 ) Chronic Liver Patient ( non cirrhotic ) : Patient diagnose chronic liver disease 6 month . Inclusion Criteria ( COPD ) : No know liver disease BMI 20 25 kg/m2 Normal liver enzyme ( ALT &lt; 40 U/L men , &lt; 30 U/L woman ) Patients COPD exacerbation elevate PCO2 level ( &gt; 50 mmHg ) Without clinically overt right heart failure Ceased smoking least one month No overt clinical dysfunction major organ system Inclusion criterion ( Smoker ) : Smokers : No know liver disease Active smoker least 10 cigarettes/day ( stable number cigarette past month currently try quit ) . BMI 20 25 kg/m2 Normal liver enzyme ( ALT &lt; 40 U/L men , &lt; 30 U/L woman ) Not take medication No know chronic medical condition Inclusion criterion ( CYP450 1A2 inhibitor ) : Healthy Subjects : No know liver disease Non smoker BMI 20 25 kg/m2 Normal liver enzyme ( ALT &lt; 40 U/L men , &lt; 30 U/L woman ) Not take medication No know chronic medical condition ( allergy orthopaedic condition require chronic therapy allow ) . Normal abdominal US Cirrhotic subject : Diagnosis cirrhosis liver biopsy Or strong suspicion cirrhosis accept criterion clinical diagnosis cirrhosis ( e.g . peripheral edema varix , palpable hard leave lobe liver , small right lobe span palpable splenomegaly ) , and/or radiological evidence cirrhosis ( abdominal sonography , computer assist axial tomography , magnetic resonance imaging , show nodular liver and/or portosystemic collateral portal vein patency and/or ascites and/or splenomegaly , and/or colloid shift colloidisotope liverspleen scan ) , and/or laboratory variable ( platelet &lt; 100,000/mm3 , albumin &lt; 3.5g/dL , INR &gt; 1.3 ) Not receive medication metabolize CYP450 1A2 Inclusion criterion ( Beta Blockers ) : Diagnosis cirrhosis ( liver biopsy clinical diagnosis ) : Strong suspicion cirrhosis accept criterion clinical diagnosis cirrhosis ( e.g . peripheral edema varix , palpable hard leave lobe liver , small right lobe span palpable splenomegaly ) , and/or radiological evidence cirrhosis ( abdominal sonography , computer assist axial tomography , magnetic resonance imaging , show nodular liver and/or portosystemic collateral portal vein patency and/or ascites and/or splenomegaly , and/or colloid shift colloidisotope liverspleen scan ) , and/or laboratory variable ( platelet &lt; 100,000/mm3 , albumin &lt; 3.5g/dL , INR &gt; 1.3 ) Naive Beta Blockers clinical indication initiate therapy ( eg . esophageal varix , portal hypertensive gastropathy ) Resting pulse &gt; 60 beat per minute Non smoker Inclusion criterion ( Alcohol ) : No know liver disease Non smoker BMI 20 25 kg/m2 Normal liver enzyme ( ALT &lt; 40 U/L men , &lt; 30 U/L woman ) Not take medication No know chronic medical condition . ( Allergy orthopaedic condition require chronic therapy allow ) . Normal abdominal US General Severe heart , pulmonary renal disease . Patient previous surgical bypass surgery morbid obesity Patient extensive small bowel resection Any major surgery past 3 month . Patient recipient organ transplant Pregnant breastfeeding woman . Patient allergic acetaminophen Patients take hepatotoxic drug Patient , base opinion investigator , enrol study . Patients unable unwilling sign inform consent Patients participate clinical trial evaluate experimental treatment procedure participate clinical trial past 3 month . Exclusion Criteria ( Day MBTgeneral ) Patient fast 8 hour . Patient smoke day test . Patient take drug interfere methacetin metabolism : fluvoxamine , amiodarone , ciprofloxacin , cimetidine , rifampin , carbamazepine within last 24 hour . Patient take Tylenol acetaminophen relate medication within past 24 hour . Patients receive new medication last 48 hour . Patients still suffer previous clinical intervention ( e.g . Have consume alcohol 24 hour prior MBT consume regular basis 40gr male 20gr female per day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Patients chronic liver disease cirrhosis</keyword>
</DOC>